London & Tokyo: 10 June 2023: Kantar, the world’s leading marketing data and analytics company, today announces the proposed sale of its remaining specialist healthcare businesses to leading healthcare marketing specialist, M3 Global Research. The assets comprise two complementary businesses.
• Kantar Profiles – Health: The Healthcare business of Kantar’s Profiles division is a leading provider of high-quality healthcare insights data for research agencies, healthcare-focused consultancies and pharma. It brings marketers in the healthcare market closer to physicians, patients, and payers so they can understand the people and trends shaping the healthcare research landscape.
• Kantar Media Healthcare Research (KMHR): The Healthcare research business of Kantar Media, KMHR is a leading provider of media measurement, audience insights and advertising intelligence for pharma and other healthcare advertisers, agencies and media companies. They help clients understand healthcare consumers (through the MARS Consumer Health study) and HCPs (through various syndicated studies); their attitudes, behaviours and media consumption habits; and the advertising to which they’re exposed.
Commenting on the announcement Chris Jansen, Chief Executive at Kantar, said: “Today we set these two great businesses on a path for continued sustainable growth and leadership. Under this proposed new ownership structure, they will have the strategic framework and ecosystem to continue growing and innovating in their industry. At the same time, Kantar can more completely focus on its strategic priorities of empowering the world’s biggest consumer companies to shape their brand future.”
Anton Richter, CEO of market research industry leading M3 Global Research, part of the M3 Group added, “By combining the strength of our existing assets and resources with those of Kantar Profiles – Health and Kantar Media Healthcare Research, we are further enhancing our capabilities in delivering high quality research data for the life sciences industry. The KMHR addition expands our business operations and lays a foundation for our continued ambitious growth in healthcare market research, whilst bolstering our service offering for our growing global client base.”
The proposed project is expected to conclude in early July 2023, subject to completion of the relevant shareholder, legal and regulatory processes and subject to the completion of information and consultation processes with employee representatives where necessary. Canaccord Genuity LLC acted as exclusive financial advisor to Kantar in the transaction. Financial details have not been disclosed.